Immunic, Inc. (IMUX)
| Market Cap | 210.12M +149.2% |
| Revenue (ttm) | n/a |
| Net Income | -111.57M |
| EPS | -4.00 |
| Shares Out | 13.64M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 357,930 |
| Open | 16.21 |
| Previous Close | 16.30 |
| Day's Range | 15.00 - 16.30 |
| 52-Week Range | 5.06 - 17.43 |
| Beta | 1.40 |
| Analysts | Strong Buy |
| Price Target | 42.18 (+173.9%) |
| Earnings Date | Aug 11, 2026 |
About IMUX
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patien... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for IMUX stock is "Strong Buy." The 12-month stock price target is $42.18, which is an increase of 173.90% from the latest price.
News
Immunic initiated with an Outperform at Wedbush
Wedbush analyst Martin Fan initiated coverage of Immunic (IMUX) with an Outperform rating and $45 price target Immunic is a clinical-stage biopharmaceutical company developing immune modulators for im...
Immunic Earnings release: Q2 2026
Immunic released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
Immunic Quarterly report: Q2 2026
Immunic has published its Q2 2026 quarterly earnings report on August 11, 2026.
Immunic reports Q2 EPS (80c), consensus ($1.16)
“During the second quarter, we continued to execute across our late-stage development priorities as we advance toward what we believe will be a transformational period for Immunic (IMUX),” said Erik…
Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update
– Leadership Team Expanded with Key Executive Appointments, Including Chief Executive Officer, Chief Medical Officer and Chair of the Board of Directors, to Support Clinical Development, as well as ND...
Immunic Appoints Elena Ridloff to Board of Directors
– Appointment Strengthens Board with Financial, Capital Markets and Commercial Leadership Expertise as the Company Approaches Pivotal Phase 3 ENSURE Readout in Relapsing Multiple Sclerosis as well as ...
Immunic Slides: Investor presentation
Immunic has posted slides in relation to its latest quarterly earnings report, which was published on July 14, 2026.
Immunic to Participate in Investor Conferences in July
NEW YORK, July 9, 2026 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced pa...
Immunic to Participate in Investor, Industry and Scientific Conferences in June
NEW YORK, June 10, 2026 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced pa...
Immunic Slides: Corporate presentation
Immunic has posted slides in relation to its latest quarterly earnings report, which was published on June 1, 2026.
Immunic Proxy statement: Proxy filing
Immunic filed a proxy statement on May 29, 2026, providing details for shareholder voting and corporate governance matters.
Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis
– Late-Breaking Poster Introduces New Unified Statistical Analyses for Assessing Confirmed Disability Changes for Trials in Progressive Multiple Sclerosis – – Additional CALLIPER Data Further Highligh...
Immunic CEO Daniel Vitt to step down, Erik Lundgren to succeed
Immunic (IMUX) announced the appointment of Erik Lundgren as CEO, effective May 22, with employment beginning on June 1. Lundgren succeeds Daniel Vitt, who will retain responsibility for scientific st...
Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer
– Proven Leader with Deep Multiple Sclerosis Expertise; Played Key Role in the Launch of Ocrevus® – – Will Leverage Senior Global Executive and Commercial Experience to Support Immunic's Transition To...
B. Riley cuts Immunic target, sees ‘compelling entry point’
B. Riley analyst William Wood lowered the firm’s price target on Immunic (IMUX) to $27 from $40 and keeps a Buy rating on the shares. The firm says the shares…
Immunic appoints Michael Bonney as chair
Immunic (IMUX) announced the appointment of Michael Bonney as chair of its board of directors, effective May 16. Simona Skerjanec will transition from interim chairperson to continue serving as a…
Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors
– More Than 30 Years of Leadership Experience Across Biopharmaceutical Commercialization – – Played Key Role in the Launch and Commercial Success of Avonex® for Multiple Sclerosis – NEW YORK, May 19, ...
Immunic price target lowered to $19 from $26 at Roth Capital
Roth Capital analyst Boobalan Pachaiyappan lowered the firm’s price target on Immunic (IMUX) to $19 from $26 but keeps a Buy rating on the shares after its Q1 earnings miss.
Immunic reports Q1 EPS ($1.08), consensus (96c)
“We are fast approaching a highly pivotal juncture, with the anticipated top-line data readout of the twin phase 3 ENSURE trials of our lead asset, orally available nuclear receptor-related 1…
Immunic Quarterly report: Q1 2026
Immunic has published its Q1 2026 quarterly earnings report on May 13, 2026.
Immunic Earnings release: Q1 2026
Immunic released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Immunic Slides: Investor presentation
Immunic has posted slides in relation to its latest quarterly earnings report, which was published on May 13, 2026.
Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update
– Appointed Globally Renowned Biopharmaceutical Executive and Neurology Drug Developer, Michael A. Panzara, M.D.
Immunic initiated with an Outperform at LifeSci Capital
LifeSci Capital analyst Sam Slutsky initiated coverage of Immunic (IMUX) with an Outperform rating and $56 price target
Immunic Registration statement: Registration filing
Immunic filed a registration statement on April 30, 2026, providing details about a securities offering with the SEC.